What type of study is this?

September 10, 2025

Suprathreshold dosing of selective serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: A case series.

View Full Paper

Ask AI

Bookmark

Authors

Case series highlights the use of supratherapeutic SSRIs in treatment-resistant OCD, suggesting potential benefits with careful monitoring.

Supratherapeutic dosing of SSRIs significantly improves symptom relief in treatment-resistant OCD patients, indicating a potential alternative approach.
Key evidence shows that higher-than-recommended SSRI doses enhance serotonergic activity, which may lead to better treatment responses for OCD.
Observational analysis of treatment-resistant OCD patients reveals variable individual responses to supratherapeutic SSRI dosing and emphasizes the need for ongoing monitoring.
This approach highlights the potential benefits of SSRIs at suprathreshold levels while also calling for further research on long-term safety in this patient group.

Saha et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Case series highlights the use of supratherapeutic SSRIs in treatment-resistant OCD, suggesting potential benefits with careful monitoring.